Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the mechanism of action on target tissue level of
anti Interleukine-17 (anti-IL-17) an therapy in peripheral spondyloarthritis.
Patients will be treated with anti-IL-17 therapy (secukinumab) for 12 weeks and with a 2 year
extension period thereafter.
At week 0 and 12 peripheral blood, synovial tissue and skin will be analysed with different
techniques, including immunohistochemistry, RNA analysis and tissue culture to assess the
effect of the therapy on inflammatory pathways.
Phase:
Phase 3
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)